09.09.2022

High HH and low AR associated with resistance to ARDT in prostate cancer

Events

In collaboration with:

ESMO2022 starts today

Naoual Menssouri from Institut Gustave Roussy, will present her findings using OncoSIGNal.

“High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer”.

Date: Saturday, September 10, 2022 | Poster Session 10 | Abstract# 1380P

Read abstract here

Contact us

E-Mail us oncosignal@innosignbio.com

Filters

InnoSIGN Launches New Suite Products for Pharmaceutical Research and Clinical Studies

InnoSIGN appoints Eric Lindquist new Chief Executive Officer

Collaboration with NYU Langone Health in breast cancer

Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers

Meet InnoSIGN at Association for Molecular Pathology (AMP) 2023

InnoSIGN starts offering OncoSIGNal pathway profiling services for clinical use in the US

InnoSIGN receives grant of almost €700K for ovarian cancer multicenter trial

Institut Gustave Roussy: OncoSIGNal predicts resistance to AR targeted drugs in mCR prostate cancer

High HH and low AR associated with resistance to ARDT in prostate cancer

Contact us

News

InnoSIGN Launches New Suite Products for Pharmaceutical Research and Clinical Studies

InnoSIGN appoints Eric Lindquist new Chief Executive Officer

Collaboration with NYU Langone Health in breast cancer

Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers

Meet InnoSIGN at Association for Molecular Pathology (AMP) 2023

InnoSIGN starts offering OncoSIGNal pathway profiling services for clinical use in the US

InnoSIGN receives grant of almost €700K for ovarian cancer multicenter trial

Institut Gustave Roussy: OncoSIGNal predicts resistance to AR targeted drugs in mCR prostate cancer

Erasmus MC: OncoSIGNal predicts response to BCG treatment of bladder cancer

Scientific symposium “Improving pediatric cancer care by scientific excellence”

Racial differences in estrogen receptor signaling pathway activity in breast cancer patients

Presentation of OncoSIGNal at the AACR

We are celebrating our 1st Business Anniversary

Fullfilled Job Opportunity:
Software / Data Engineer

Presentation of OncoSIGNal analysis of samples from NeoLBC breast cancer trial

Online symposium “Promising Biotech Startups”

Webinar IVD for Oncology: Guiding Clinical Trials and Patient Treatment through Precision Medicine

The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy

InnoSIGN welcomes Mark Oldroyd as Board Member

InnoSIGN aims to increase survival rates of cancer patients using PCR tests

InnoSIGN wins Gerard & Anton Award

High HH and low AR associated with resistance to ARDT in prostate cancer

$9.2 M raised during Series A investment round

InnoSIGN is developing a smart PCR test to predict which drug will work in a cancer patient

Interview with Sr. Investment Manager BOM and CEO InnoSIGN

PCR test predicts which medication will best work

InnoSIGN completes spin-out from Philips, $8M Series A

Signaling pathways in high-grade serous ovarian carcinoma

High HH and low AR associated with resistance to ARDT in prostate cancer

Contact us

News

InnoSIGN Launches New Suite Products for Pharmaceutical Research and Clinical Studies

InnoSIGN appoints Eric Lindquist new Chief Executive Officer

Collaboration with NYU Langone Health in breast cancer

Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers

Meet InnoSIGN at Association for Molecular Pathology (AMP) 2023

InnoSIGN starts offering OncoSIGNal pathway profiling services for clinical use in the US

InnoSIGN receives grant of almost €700K for ovarian cancer multicenter trial

Institut Gustave Roussy: OncoSIGNal predicts resistance to AR targeted drugs in mCR prostate cancer

Erasmus MC: OncoSIGNal predicts response to BCG treatment of bladder cancer

Scientific symposium “Improving pediatric cancer care by scientific excellence”

Racial differences in estrogen receptor signaling pathway activity in breast cancer patients

Presentation of OncoSIGNal at the AACR

We are celebrating our 1st Business Anniversary

Fullfilled Job Opportunity: Software / Data Engineer

Presentation of OncoSIGNal analysis of samples from NeoLBC breast cancer trial

Online symposium “Promising Biotech Startups”

Webinar IVD for Oncology: Guiding Clinical Trials and Patient Treatment through Precision Medicine

The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy

InnoSIGN welcomes Mark Oldroyd as Board Member

InnoSIGN aims to increase survival rates of cancer patients using PCR tests

InnoSIGN wins Gerard & Anton Award

High HH and low AR associated with resistance to ARDT in prostate cancer

$9.2 M raised during Series A investment round

InnoSIGN is developing a smart PCR test to predict which drug will work in a cancer patient

Interview with Sr. Investment Manager BOM and CEO InnoSIGN

PCR test predicts which medication will best work

InnoSIGN completes spin-out from Philips, $8M Series A

Signaling pathways in high-grade serous ovarian carcinoma

Cookies

Fullfilled Job Opportunity:
Software / Data Engineer